Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference
November 06 2013 - 6:45AM
Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will webcast its
corporate presentation at the 2013 Credit Suisse Healthcare
Conference on Wednesday, November 13, 2013, at 4:00 pm Mountain, or
6:00 pm Eastern.
The presentation will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar.
Presentation slides will be available via the webcast link. A
replay of the webcast will also be available on Sucampo's website
for several days after the live event. To ensure a timely
connection, it is recommended that users register at least 15
minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the discovery,
development and commercialization of drugs based on ion channel
activators knows as prostones. Discovered by the company's
scientific founder, prostones are naturally occurring fatty acid
metabolites with unique physiological activities. Sucampo has two
marketed products – AMITIZA® and RESCULA® – and a pipeline of
prostone-based product candidates in clinical development. A global
company, Sucampo is headquartered in Bethesda, Maryland, and has
operations in the United Kingdom, Switzerland and Japan. For more
information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG. RESCULA is a registered trademark of
R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; Sucampo's ability to accurately predict
future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or
regulatory actions. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates
by reference.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
CONTACT: Silvia Taylor
Senior Vice President, IR, PR, and Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Oct 2023 to Oct 2024